Atara Biotherapeutics, Inc.
2659 Townsgate Road
Suite 236
Thousand Oaks
California
91361
United States
277 articles about Atara Biotherapeutics, Inc.
-
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
12/14/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced efficacy and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel®) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).
-
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
-
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
12/9/2021
Atara Biotherapeutics, Inc. today announced new preclinical and preliminary clinical results for ATA2271, a next-generation autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin (MSLN).
-
Atara Biotherapeutics Reported Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3/2021
Atara Biotherapeutics, Inc. today reported the grant of an aggregate of 21,438 restricted stock units of Atara’s common stock to seven newly hired employees and stock options to purchase an aggregate of 24,017 shares.
-
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
11/30/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the Marketing Authorization Application (MAA) for tabelecleucel (tab-cel®) has been fully validated by the European Medicines Agency (EMA).
-
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced that Pascal Touchon, President and Chief Executive Officer of Atara, will participate at three upcoming virtual conferences.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 05, 2021
11/5/2021
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 52,474 restricted stock units of Atara’s common stock to 15 newly hired employees and stock options to purchase an aggregate of 5,618 shares of Atara’s common stock to one such newly hired employee.
-
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
11/4/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its Phase 3 ALLELE study.
-
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
11/4/2021
Atara Biotherapeutics, Inc. today reported financial results for the third quarter 2021, recent business highlights and key catalysts over the next several months.
-
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
10/28/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021.
-
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
10/13/2021
Atara Biotherapeutics, Inc. today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase 1 open-label extension (OLE) clinical data in patients with progressive multiple sclerosis (MS) treated with ATA188 for up to 39 months.
-
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
10/4/2021
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel ® )
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Oct 01, 2021
10/1/2021
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 104,386 restricted stock units of Atara’s common stock to 16 newly hired employees and stock options to purchase an aggregate of 107,813 shares of Atara’s common stock to five such newly hired employees.
-
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
9/29/2021
Atara Biotherapeutics, Inc., announced the upcoming full release of new translational data and two-year open-label extension clinical data from the study of ATA188 in progressive multiple sclerosis.
-
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
9/27/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Company’s lead product candidate, tabelecleucel (tab-cel®), for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Sep 03, 2021
9/3/2021
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 74,055 restricted stock units of Atara’s common stock to 16 newly hired employees and stock options to purchase an aggregate of 59,869 shares of Atara’s common stock to five such newly hired employees.
-
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
9/2/2021
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled, “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” at the Citi 16th Annual BioPharma Virtual Conference
-
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
8/9/2021
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of Ameet Mallik to the Board of Directors.
-
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
8/9/2021
Atara Biotherapeutics, Inc. today reported financial results for the second quarter 2021, recent business highlights and key catalysts over the next several months.
-
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
8/2/2021
Atara Biotherapeutics, Inc. today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.